
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp demonstrated robust financial performance, with its burn care franchise experiencing a 22% year-over-year growth, reaching $39.9 million in FY2024, reflecting effective salesforce expansion which is anticipated to continue driving high-single-digit growth into 2025. The company's MACI product also showed significant momentum, reporting a notable 21% year-over-year growth to $68.3 million in the fourth quarter of 2024, supported by a three-year compound annual growth rate (CAGR) of 20.9% and promising new product launches. Moreover, guidance indicates a strong gross margin of approximately 73-74%, and projected revenue growth between 20-23% for 2025, suggesting a potential inflection point for profitability that could positively influence investor sentiment.
Bears say
Vericel Corp's negative outlook is primarily underscored by a series of recent performance misses and emerging concerns regarding its growth trajectory. The reported revenue of $75.4 million in the fourth quarter fell short of earlier expectations, particularly driven by underperformance in key products like Epicel and NexoBrid, with management citing patient health issues and fewer grafts per patient as contributing factors. Additionally, the risks associated with market dynamics, potential recession impacts, and the delayed uptake of newer therapies further exacerbate the uncertainty surrounding the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares